ClinicalTrials.gg
Active, not recruitingNCT07534592Updated Nov 10, 2026

A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants

A Phase 1 interventional study of Elecoglipron and Atorvastatin in Healthy Participants, sponsored by AstraZeneca. Active, not recruiting at 2 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Updated Nov 10, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies testing elecoglipron in Diabetes Mellitus, Type 2 — 6 open to participants now, 7 under way, 6 of them phase 3. elecoglipron · Diabetes Mellitus, Type 2.

Enrollment
11th of 18
48 · median 57
Started
2026
with 8 others
Phase 1
11 of 18
none open now
Registered
12th of 18
by date
Lead sponsor
14 of 18
AstraZeneca

Among the 18 studies testing elecoglipron in Diabetes Mellitus, Type 2, this one is the 11th largest by enrollment, is one of 9 that started in 2026, is one of 11 in phase 1, and was the 12th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

6 of the 18 studies testing elecoglipron in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About elecoglipron

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing elecoglipron in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The study has 2 groups, one each focusing on co-administration of elecoglipron and atorvastatin or rosuvastatin to assess the pharmacokinetics (PK) of atorvastatin in healthy participants.

Read the detailed description

This is an open-label, fixed-sequence, conducted at 2 study centers with 2 groups.

Group 1 is designed to assess the PK of atorvastatin in healthy participants when administered alone and in combination with multiple doses of elecoglipron. This group will consist of a screening period, 6 treatment periods, and a follow-up visit. Each participant in Group 1 will be involved in the study for approximately 15 weeks.

Group 2 is designed to assess the PK of rosuvastatin in healthy participants when administered alone and in combination with multiple doses of elecoglipron. This group will consist of a screening period, 7 treatment periods, and a follow-up visit. Each participant in Group 2 will be involved in the study for approximately 16 weeks.

Group 1 and Group 2 are independent and non-sequential parts in this study. All parts of this study will be performed in healthy male and female participants

03

Conditions studied

  • Healthy Participants

Keywords

  • Pharmacokinetics
  • Statin exposure
  • Fixed sequence
  • Type 2 diabetes
  • Obesity
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All females must have a negative pregnancy test at the Screening Visit and on admission to the Clinical Unit.
  • Females of must not be lactating and if heterosexually active, must agree to use an approved method of highly effective throughout the study.
  • Females of non-childbearing potential must be confirmed as or have documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy but not tubal ligation or tubal occlusion at screening visit.
  • Sexually active fertile male participants with partners of childbearing potential must adhere to the contraception methods.

Exclusion criteria

Exclusion Criteria:

  • History of any disease or disorder.
  • Participants with cardiovascular diseases, neuromuscular or neurogenic disease, type 1 or type 2 diabetes mellitus, or positive for (HIV), or uncontrolled thyroid disease.
  • History of acute pancreatitis, history or presence of gastrointestinal (GI) or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
  • Clinically significant inflammatory bowel disease, gastroparesis, severe disease, or surgery affecting the upper GI tract.
  • Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of study intervention.
  • Any clinically important abnormalities in laboratory values, clinical chemistry, hematology, urinalysis results, or vital signs.
  • Any clinically important abnormalities in rhythm, conduction, or morphology of the resting 12-lead at screening.
  • History of severe allergy/ or ongoing clinically important allergy/hypersensitivity to drugs with a similar chemical structure or class to elecoglipron or paracetamol.
  • Participants who have previously received elecoglipron within the last 6 months or was on statin treatment for ≤ 4 weeks prior to the study treatment.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Group 1: Period 1

    Participants will receive a single dose of atorvastatin on Day 1.

    Drug: Atorvastatin

  • Experimental
    Group 1: Period 2

    Participants will receive single dose of atorvastatin on Day 5 and then receive multiple doses of elecoglipron from Day 7 to Day 40.

    Drug: Elecoglipron · Drug: Atorvastatin

  • Experimental
    Group 1: Period 3

    Participants will receive single dose of atorvastatin on Day 41 and then receive multiple doses of elecoglipron from Day 41 to Day 43.

    Drug: Elecoglipron · Drug: Atorvastatin

  • Experimental
    Group 1: Period 4

    Participants will receive elecoglipron in the morning and a single dose of atorvastatin in the evening on Day 44. Participant will continue elecoglipron on Day 45. Participants will receive daily administration of different doses of elecoglipron alone from Day 46 to Day 58.

    Drug: Elecoglipron · Drug: Atorvastatin

  • Experimental
    Group 1: Period 5

    Participants will receive single dose of atorvastatin and elecoglipron on Day 59. Participants will receive elecoglipron alone on Day 60 to Day 61.

    Drug: Elecoglipron · Drug: Atorvastatin

  • Experimental
    Group 1: Period 6

    Participants will receive elecoglipron in the morning and a single dose of atorvastatin in the evening on Day 62. Participant will continue elecoglipron alone from Day 63 to Day 64.

    Drug: Elecoglipron · Drug: Atorvastatin

  • Experimental
    Group 2: Period 1

    Participants will receive single dose of rosuvastatin on Day 1 and then multiple doses of elecoglipron from Day 5 to Day 38.

    Drug: Elecoglipron · Drug: Rosuvastatin

  • Experimental
    Group 2: Period 2

    Participants will receive elecoglipron in the morning along with a single dose of rosuvastatin on Day 39. Participant will continue elecoglipron alone from Day 40 to Day 44.

    Drug: Elecoglipron · Drug: Rosuvastatin

  • Experimental
    Group 2: Period 3

    Participants will receive elecoglipron in the morning and a single dose of rosuvastatin in the evening on Day 45. Participant will continue on different doses of elecoglipron alone from Day 46 to Day 59.

    Drug: Elecoglipron · Drug: Rosuvastatin

  • Experimental
    Group 2: Period 4

    Participants will receive elecoglipron in the morning along with a single dose of rosuvastatin on Day 60. Participant will continue elecoglipron alone from Day 61 to Day 65.

    Drug: Elecoglipron · Drug: Rosuvastatin

  • Experimental
    Group 2: Period 5

    Participants will receive elecoglipron in the morning and a single dose of rosuvastatin in the evening on Day 66. Participant will continue on elecoglipron alone from Day 67 to Day 69 and from Day 73 to Day 86.

    Drug: Elecoglipron · Drug: Rosuvastatin

  • Experimental
    Group 2: Period 6

    Participants will receive elecoglipron and a single dose of rosuvastatin in the morning on Day 87. Participants will continue elecoglipron from Day 87 to Day 91.

    Drug: Elecoglipron · Drug: Rosuvastatin

  • Experimental
    Group 2: Period 7

    Participants will receive a single dose of rosuvastatin in the morning on Day 106.

    Drug: Rosuvastatin

Interventions

  • Elecoglipron will be administered as oral tablet.

  • Atorvastatin will be administered as oral tablet.

  • Rosuvastatin will be administered as oral tablet.

06

What researchers measure

Primary outcomes

  1. Area under concentration-time curve from time 0 to infinity (AUCinf) of atorvastatin

    To assess the effect of multiple doses of elecoglipron on the PK of a single dose of atorvastatin in healthy participants.

    Time frame: Group 1: Day 1 to Day 71

  2. Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast) of atorvastatin

    To assess the effect of multiple doses of elecoglipron on the PK of a single dose of atorvastatin in healthy participants.

    Time frame: Group 1: Day 1 to Day 71

  3. Maximum observed drug concentration (Cmax) of atorvastatin

    To assess the effect of multiple doses of elecoglipron on the PK of a single dose of atorvastatin in healthy participants.

    Time frame: Group 1: Day 1 to Day 71

  4. AUCinf of rosuvastatin

    To assess the effect of multiple doses of elecoglipron on the PK of a single dose of rosuvastatin in healthy participants.

    Time frame: Group 2: Day 1 to Day 76

  5. AUClast of rosuvastatin

    To assess the effect of multiple doses of elecoglipron on the PK of a single dose of rosuvastatin in healthy participants.

    Time frame: Group 2: Day 1 to Day 76

  6. Cmax of rosuvastatin

    To assess the effect of multiple doses of elecoglipron on the PK of a single dose of rosuvastatin in healthy participants.

    Time frame: Group 2: Day 1 to Day 76

  7. Ratio of Atorvastatin (Atorvastatin + elecoglipron) to Atorvastatin (alone) based on AUCinf (R AUCinf) of atorvastatin

    To assess the effect of multiple doses of elecoglipron on the PK of a single dose of atorvastatin in healthy participants.

    Time frame: Group 1: Day 1 to Day 71

  8. Ratio of Atorvastatin (Atorvastatin + elecoglipron) to Atorvastatin (alone) based on AUClast (R AUClast) of atorvastatin

    To assess the effect of multiple doses of elecoglipron on the PK of a single dose of atorvastatin in healthy participants.

    Time frame: Group 1: Day 1 to Day 71

  9. Ratio of Atorvastatin (Atorvastatin + elecoglipron) to Atorvastatin (alone) based on Cmax (R Cmax) of atorvastatin

    To assess the effect of multiple doses of elecoglipron on the PK of a single dose of atorvastatin in healthy participants.

    Time frame: Group 1: Day 1 to Day 71

  10. Terminal elimination half-life (t1/2λz) of atorvastatin

    To assess the effect of multiple doses of elecoglipron on the PK of a single dose of atorvastatin in healthy participants.

    Time frame: Group 1: Day 1 to Day 71

  11. Terminal rate constant (λz) of atorvastatin

    To assess the effect of multiple doses of elecoglipron on the PK of a single dose of atorvastatin in healthy participants.

    Time frame: Group 1: Day 1 to Day 71

  12. Time to reach maximum observed concentration (tmax) of atorvastatin

    To assess the effect of multiple doses of elecoglipron on the PK of a single dose of atorvastatin in healthy participants.

    Time frame: Group 1: Day 1 to Day 71

  13. Ratio of Rosuvastatin (Rosuvastatin + elecoglipron) to Rosuvastatin (alone) based on AUCinf (R AUCinf) of rosuvastatin

    To assess the effect of multiple doses of elecoglipron on the PK of a single dose of rosuvastatin in healthy participants.

    Time frame: Group 2: Day 1 to Day 76

  14. Ratio of Rosuvastatin (Rosuvastatin + elecoglipron) to Rosuvastatin (alone) based on AUClast (R AUClast) of rosuvastatin

    To assess the effect of multiple doses of elecoglipron on the PK of a single dose of rosuvastatin in healthy participants.

    Time frame: Group 2: Day 1 to Day 76

  15. Ratio of Rosuvastatin (Rosuvastatin + elecoglipron) to Rosuvastatin (alone) based on Cmax (R Cmax) of rosuvastatin

    To assess the effect of multiple doses of elecoglipron on the PK of a single dose of rosuvastatin in healthy participants.

    Time frame: Group 2: Day 1 to Day 76

  16. t1/2λz of rosuvastatin

    To assess the effect of multiple doses of elecoglipron on the PK of a single dose of rosuvastatin in healthy participants.

    Time frame: Group 2: Day 1 to Day 76

  17. λz of rosuvastatin

    To assess the effect of multiple doses of elecoglipron on the PK of a single dose of rosuvastatin in healthy participants.

    Time frame: Group 2: Day 1 to Day 76

  18. tmax of rosuvastatin

    To assess the effect of multiple doses of elecoglipron on the PK of a single dose of rosuvastatin in healthy participants.

    Time frame: Group 2: Day 1 to Day 76

Secondary outcomes

  1. Number of participants with adverse events (AEs) and adverse event of special interest (AESI)

    To examine the safety and tolerability of elecoglipron alone and in combination with atorvastatin (Group 1) or rosuvastatin (Group 2) in healthy participants.

    Time frame: Group 1: Day -28 to Day 74; Group 2: Day -28 to Day 79

07

Study locations

2 sites
  • Research Site
    Glendale, California 91206, United States
  • Research Site
    Brooklyn, Maryland 21225, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptriaIs.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/ Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jan 2027, 9 months after the start.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's planned 9 months is above that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Oct 2026 → Jan 2027 and completion Oct 2026 → Jan 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2026
First posted
Apr 16, 2026
StartActual
Apr 16, 2026
Primary completionEst.
Jan 25, 2027was Oct 2026
CompletionEst.
Jan 25, 2027was Oct 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 1, 2026→Jan 25, 2027
Nov 10, 2026
Study completion
Oct 1, 2026→Jan 25, 2027
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Primary completion Oct 1, 2026→Jan 25, 2027
    Study completion Oct 1, 2026→Jan 25, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07534592
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
Apr 16, 2026
Start date
Apr 16, 2026
Primary completion
Jan 25, 2027 (estimated)
Completion
Jan 25, 2027 (estimated)
Last update
Nov 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elecoglipron · Atorvastatin · Rosuvastatin

Start the discussion